Scaling Healthcare Investment India through Fund III

Somerset Indus Capital Partners recently announced the final close of its third fund, focusing on healthcare investment India. This fund reached approximately $288 million, which significantly exceeded the initial target of $250 million. Consequently, the firm aims to support affordable and accessible care in tier I and tier II cities. The capital will target sectors like pharmaceuticals, medical devices, and diagnostics. Furthermore, the participation from global and domestic investors underscores strong confidence in the Indian market.

Notably, the fund attracted interest from development finance institutions and family offices across Europe and the United States. Somerset typically invests between $15 million and $40 million per portfolio company. However, they can participate in larger transactions reaching $80 million through co-investment syndication. This strategy allows the firm to partner with entrepreneurs building scalable platforms. Therefore, these investments will likely drive innovation in preventive care and outpatient services.

Targeting Underserved Markets and Innovation

The additional capital will specifically support opportunities in medical technology and OPD-linked insurance. Additionally, the firm plans to focus on diagnostics platforms that improve access beyond metro markets. Through Fund III, Somerset has already committed capital to three distinct businesses. These include Cyrix Healthcare, a medical equipment firm, and NU Hospitals, a Bengaluru-based hospital chain. Such diverse investments reflect a commitment to building a comprehensive healthcare ecosystem.

The firm has demonstrated a strong track record with its previous funds. For instance, Fund I returned four times the total capital to its investors. Similarly, Fund II is progressing toward successful exits, with its first realization also achieving a fourfold return. Consequently, these results validate Somerset's execution capabilities in the private equity space. The firm now manages around $500 million in total assets across its three flagship funds.

Frequently Asked Questions

Q1: What is the primary focus of Somerset Indus Fund III?

The fund focuses on healthcare delivery, pharmaceuticals, medical devices, diagnostics, and allied segments across India's tier I and tier II cities.

Q2: Which companies has Fund III already invested in?

Somerset has already made investments in Kerala-based Cyrix Healthcare, pharmaceutical packaging firm Printmann Offset, and Bengaluru-based NU Hospitals.

Q3: How much does Somerset typically invest in a single company?

The firm usually invests between $15 million and $40 million, but can participate in deals up to $80 million via co-investment networks.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.

References

1. PE firm Somerset Indus closes $288 million Fund III, beats target - ETHealthworld


2. Somerset Indus Capital Partners Portfolio and Fund Overview.


3. Indian Private Equity & Venture Capital Association (IVCA) Healthcare Sector Report 2025.